Developer docs
API playgroundTry for free, no card

Search company profiles

Acadia Pharmaceuticals Inc.

Full company profile

uuid0000pk5

Namestring
Acadia Pharmaceuticals Inc.
Legal namestring
Acadia Pharmaceuticals Inc.
Company typeenum
Public
Founded yearint
1993
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
central nervous system drugs, rare disease therapeutics, neurological disorder therapies, Parkinson's disease treatments, biopharmaceutical products
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neurology Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Acadia generates revenue through the sale of prescription pharmaceutical products, primarily NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome. Revenue is generated through traditional pharmaceutical distribution channels including specialty pharmacies and direct hospital sales. The company reported Q4 2025 net income of $274 million ($1.60 per diluted share) compared to $144 million in Q4 2024, including a $250 million non-cash income tax benefit related to deferred tax assets.

businesswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1NUPLAZID
Description

FDA-approved treatment for Parkinson's Disease Psychosis

acadia.com
+2 more records
Core offering1 text field

Acadia Pharmaceuticals develops and commercializes FDA-approved small molecule drugs for central nervous system (CNS) disorders and rare neurological diseases. The company markets two commercial brands — NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome — and is developing a pipeline that includes remlifanserin for Alzheimer's disease psychosis, ACP-211 for depression, ACP-711 for essential tremor, and GPR88 agonists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Q1 2026 revenue of $268M, up 11% year-over-year
+4 more records
Product overview1 text field

Acadia Pharmaceuticals is a biopharmaceutical company focused on neurological disorders and rare diseases. The company operates two FDA-approved commercial brands: NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome. DAYBUE STIX is a new powder formulation of trofinetide launched in 2026. The pipeline includes remlifanserin in Phase 2 for Alzheimer's disease psychosis, ACP-211 for depression, ACP-711 for essential tremor, and GPR88 agonists in preclinical research. Combined net sales projections for NUPLAZID and DAYBUE reach approximately $1.7 billion by 2028.

Product and service1 record
1NUPLAZID® (pimavanserin)
Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-02-24
Description

Acadia Pharmaceuticals is a premier sponsor of the Michael J. Fox Foundation's national event series 'Parkinson's IQ + You,' which has visited 23 cities since 2019. The event educates and empowers people living with Parkinson's disease and their families through interactive panels, research discussions, and a partner expo featuring local and national Parkinson's organizations. The March 2026 event is scheduled in Henderson, Nevada.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Stoke Therapeutics recognized $10.6 million in revenue from contractual partnerships with Acadia Pharmaceuticals and Biogen. This partnership relates to Stoke's development of genetics-based medicines for severe diseases including Dravet syndrome, with zorevunersen in Phase 3 trials under Breakthrough Therapy Designation. The partnership involves Acadia as a contractual partner contributing to Stoke's development efforts.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty CNS pharmaceutical company focused on neuropsychiatric disorders (CAPLYTA for schizophrenia/bipolar depression). Direct competitor in CNS specialty pharma targeting similar physician channels (psychiatrists/neurologists) with a single-asset commercial focus analogous to Acadia's NUPLAZID/DAYBUE model.

TypeDirect peer
Description

CNS-focused commercial-stage biopharma with FDA-approved products (AUVELITY for depression, SYMBRAVO for migraine). Comparable to Acadia as a mid-cap CNS specialty company driving revenue growth through focused sales-force deployment in under-met neurological/psychiatric indications.

TypeDirect peer
Description

Specialty pharma focused on CNS disorders including Parkinson's disease (QELBREE, APOKYN). Directly comparable business model of commercializing specialty CNS products through focused field forces targeting neurologists and movement disorder specialists.

TypeDirect peer
Description

Specialty pharma commercializing KORLYM (mifepristone) for Cushing's syndrome with a pipeline in neurological/psychiatric indications. Comparable to Acadia as a small/mid-cap CNS-focused commercial-stage company with concentrated product revenue and selective R&D investment.

TypeDirect peer
Description

Specialty pharma commercializing ZTALMY (ganaxolone) for rare neurological disorders including CDKL5 deficiency disorder. Closely comparable to Acadia in rare/ultra-rare neurological disease focus, small commercial footprint, and orphan disease commercialization.

TypeDirect peer
Description

Specialty pharma commercializing WAKIX for narcolepsy with pipeline assets in rare neurological disorders. Comparable to Acadia in mid-cap CNS specialty pharma with focused neurology sales channels and rare disease commercial expertise.

TypeEmerging player
Description

Was a CNS specialty biopharma commercializing ZURZUVAE (zuranolone) for postpartum depression; acquired by Biogen in 2025. Highly relevant historical peer to Acadia as a CNS-focused innovator with first-in-class approvals in neuropsychiatric indications.

TypeEmerging player
Description

Clinical-stage biopharma applying AI to neuroinflammation and neuropsychiatry, with IGALMI approved for agitation in schizophrenia/bipolar. Comparable emerging CNS specialty player with a smaller commercial footprint than Acadia but overlapping neurologist/psychiatrist channels.

TypeBroad incumbent
Description

Large biopharma with broad CNS/neurology portfolio (multiple sclerosis, SMA, Alzheimer's via LEQEMBI, depression via ZURZUVAE). Broader incumbent overlap with Acadia's CNS focus, particularly relevant as Alzheimer's disease psychosis and rare neurological disease expansion are pursued.

TypeBroad incumbent
Description

Large-cap pharma with deep CNS/neurology pipeline (KISUNLA for Alzheimer's, migraine therapies). Broad incumbent with overlapping therapeutic areas (Parkinson's, Alzheimer's) where Acadia's specialty products compete for share of voice with HCPs and payers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acadia Pharmaceuticals Inc.

Neurology Pharmaceuticalsacadia-pharm.com

Acadia Pharmaceuticals Inc. firmographics

Firmographics
Name
Acadia Pharmaceuticals Inc.
Legal name
Acadia Pharmaceuticals Inc.
Website
https://acadia-pharm.com
Company type
Public
Founded year
1993
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Acadia Pharmaceuticals Inc. industry classification

Industry
Product category
Neurology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Central nervous system drugs
  • Rare disease therapeutics
  • Neurological disorder therapies
  • Parkinson's disease treatments
  • Biopharmaceutical products

Where Acadia Pharmaceuticals Inc. is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Acadia Pharmaceuticals Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Operations, Others

Revenue model

  1. Pharmaceutical Product Sales: Acadia generates revenue through the sale of prescription pharmaceutical products, primarily NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome. Revenue is generated through traditional pharmaceutical distribution channels including specialty pharmacies and direct hospital sales. The company reported Q4 2025 net income of $274 million ($1.60 per diluted share) compared to $144 million in Q4 2024, including a $250 million non-cash income tax benefit related to deferred tax assets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Acadia Pharmaceuticals Inc. product offering

Product offering

Core offering

Acadia Pharmaceuticals develops and commercializes FDA-approved small molecule drugs for central nervous system (CNS) disorders and rare neurological diseases. The company markets two commercial brands — NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome — and is developing a pipeline that includes remlifanserin for Alzheimer's disease psychosis, ACP-211 for depression, ACP-711 for essential tremor, and GPR88 agonists.

Product overview

Acadia Pharmaceuticals is a biopharmaceutical company focused on neurological disorders and rare diseases. The company operates two FDA-approved commercial brands: NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome. DAYBUE STIX is a new powder formulation of trofinetide launched in 2026. The pipeline includes remlifanserin in Phase 2 for Alzheimer's disease psychosis, ACP-211 for depression, ACP-711 for essential tremor, and GPR88 agonists in preclinical research. Combined net sales projections for NUPLAZID and DAYBUE reach approximately $1.7 billion by 2028.

Differentiator

Problem solved

Functional benefit

Brands

  • NUPLAZID: FDA-approved treatment for Parkinson's Disease Psychosis
  • DAYBUE
  • DAYBUE STIX

Products and services

  • NUPLAZID® (pimavanserin)

Quantifiable outcome

  • Q1 2026 revenue of $268M, up 11% year-over-year
  • +4 more outcomes

Companies that use Acadia Pharmaceuticals Inc.

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Acadia Pharmaceuticals Inc. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Acadia Pharmaceuticals Inc. partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Michael J. Fox Foundation for Parkinson's ResearchcoreGTM or Marketing Partner · 24 February 2026Acadia Pharmaceuticals is a premier sponsor of the Michael J. Fox Foundation's national event series 'Parkinson's IQ + You,' which has visited 23 cities since 2019. The event educates and empowers people living with Parkinson's disease and their families through interactive panels, research discussions, and a partner expo featuring local and national Parkinson's organizations. The March 2026 event is scheduled in Henderson, Nevada.
  • Stoke TherapeuticsminorStrategic or Co-development Partner · 5 November 2025Stoke Therapeutics recognized $10.6 million in revenue from contractual partnerships with Acadia Pharmaceuticals and Biogen. This partnership relates to Stoke's development of genetics-based medicines for severe diseases including Dravet syndrome, with zorevunersen in Phase 3 trials under Breakthrough Therapy Designation. The partnership involves Acadia as a contractual partner contributing to Stoke's development efforts.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Acadia Pharmaceuticals Inc. competitors and assessment

Company assessment

Direct peers

  • Intra-Cellular Therapies: Specialty CNS pharmaceutical company focused on neuropsychiatric disorders (CAPLYTA for schizophrenia/bipolar depression). Direct competitor in CNS specialty pharma targeting similar physician channels (psychiatrists/neurologists) with a single-asset commercial focus analogous to Acadia's NUPLAZID/DAYBUE model.
  • Axsome Therapeutics: CNS-focused commercial-stage biopharma with FDA-approved products (AUVELITY for depression, SYMBRAVO for migraine). Comparable to Acadia as a mid-cap CNS specialty company driving revenue growth through focused sales-force deployment in under-met neurological/psychiatric indications.
  • Supernus Pharmaceuticals: Specialty pharma focused on CNS disorders including Parkinson's disease (QELBREE, APOKYN). Directly comparable business model of commercializing specialty CNS products through focused field forces targeting neurologists and movement disorder specialists.
  • Corcept Therapeutics: Specialty pharma commercializing KORLYM (mifepristone) for Cushing's syndrome with a pipeline in neurological/psychiatric indications. Comparable to Acadia as a small/mid-cap CNS-focused commercial-stage company with concentrated product revenue and selective R&D investment.
  • Marinus Pharmaceuticals: Specialty pharma commercializing ZTALMY (ganaxolone) for rare neurological disorders including CDKL5 deficiency disorder. Closely comparable to Acadia in rare/ultra-rare neurological disease focus, small commercial footprint, and orphan disease commercialization.
  • Harmony Biosciences: Specialty pharma commercializing WAKIX for narcolepsy with pipeline assets in rare neurological disorders. Comparable to Acadia in mid-cap CNS specialty pharma with focused neurology sales channels and rare disease commercial expertise.

Emerging players

  • Sage Therapeutics (now part of Biogen): Was a CNS specialty biopharma commercializing ZURZUVAE (zuranolone) for postpartum depression; acquired by Biogen in 2025. Highly relevant historical peer to Acadia as a CNS-focused innovator with first-in-class approvals in neuropsychiatric indications.
  • BioXcel Therapeutics: Clinical-stage biopharma applying AI to neuroinflammation and neuropsychiatry, with IGALMI approved for agitation in schizophrenia/bipolar. Comparable emerging CNS specialty player with a smaller commercial footprint than Acadia but overlapping neurologist/psychiatrist channels.

Broad incumbents

  • Biogen: Large biopharma with broad CNS/neurology portfolio (multiple sclerosis, SMA, Alzheimer's via LEQEMBI, depression via ZURZUVAE). Broader incumbent overlap with Acadia's CNS focus, particularly relevant as Alzheimer's disease psychosis and rare neurological disease expansion are pursued.
  • Eli Lilly: Large-cap pharma with deep CNS/neurology pipeline (KISUNLA for Alzheimer's, migraine therapies). Broad incumbent with overlapping therapeutic areas (Parkinson's, Alzheimer's) where Acadia's specialty products compete for share of voice with HCPs and payers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights7 records

Customer concentration

Acadia Pharmaceuticals Inc. social profiles

Digital presence

Acadia Pharmaceuticals Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acadia Pharmaceuticals Inc. leadership team

Management profile

Number of profiles

Profiles7 records

Acadia Pharmaceuticals Inc. funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acadia Pharmaceuticals Inc. M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acadia Pharmaceuticals Inc.

What does Acadia Pharmaceuticals Inc. do?

Acadia Pharmaceuticals develops and commercializes FDA-approved small molecule drugs for central nervous system (CNS) disorders and rare neurological diseases. The company markets two commercial brands — NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome — and is developing a pipeline that includes remlifanserin for Alzheimer's disease psychosis, ACP-211 for depression, ACP-711 for essential tremor, and GPR88 agonists.

Is Acadia Pharmaceuticals Inc. a public or private company?

Acadia Pharmaceuticals Inc. is a public company. It is classified as public and is currently operating.

When was Acadia Pharmaceuticals Inc. founded?

Acadia Pharmaceuticals Inc. was founded in 1993. It employs 501 to 1,000 people.

Where is Acadia Pharmaceuticals Inc. based?

Acadia Pharmaceuticals Inc. is headquartered in San Diego, United States, in the North America region.

How does Acadia Pharmaceuticals Inc. make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Acadia Pharmaceuticals Inc.'s main competitors?

Direct peers on record are Intra-Cellular Therapies, Axsome Therapeutics, Supernus Pharmaceuticals, Corcept Therapeutics, Marinus Pharmaceuticals and Harmony Biosciences. Emerging players are Sage Therapeutics (now part of Biogen) and BioXcel Therapeutics. Broad incumbents are Biogen and Eli Lilly.

Does Acadia Pharmaceuticals Inc. have an API?

No public API is recorded for Acadia Pharmaceuticals Inc..

What industry is Acadia Pharmaceuticals Inc. in?

Acadia Pharmaceuticals Inc.'s product category is Neurology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldACADIA Pharmaceuticals Inc. $ACAD Stock: Bessemer Group Inc. Boosts HoldingsBessemer Group Inc. increased its stake in ACADIA Pharmaceuticals by 100.3% in Q3, holding 301,008 shares worth $6.065 million. ACADIA reported Q3 EPS of $0.31, beating estimates, with revenue of $342.30 million up 22.8% year-over-year. Analysts rate the stock a Moderate Buy with a consensus price target of $31.13.Defense WorldACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue SurgeACADIA Pharmaceuticals reported Q3 revenue of $342 million, up 22% year-over-year, with DAYBUE revenue rising 39% to $140 million. The company raised its annual DAYBUE revenue guidance to $505–520 million and plans strategic business development alongside internal pipeline investment.MarketBeatACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue SurgeACADIA Pharmaceuticals reported quarterly revenue of $342 million, up 22% year-over-year, with DAYBUE revenue rising 39% to $140 million and NUPLAZID up 12% to $202 million. The company raised its annual DAYBUE revenue guidance to $505–$520 million and plans to use its $970 million balance sheet for strategic deals and pipeline investment.Seeking AlphaAcadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 TranscriptAcadia Pharmaceuticals reported Q4 revenue of $342 million, up 22% year-over-year, with DAYBUE at $140 million and NUPLAZID at $202 million. The company raised its full-year guidance to $505-520 million and received weight-banded dosing approval for DAYBUE, extending U.S. protection to 2041.Investing.comAcadia presents additional data on Alzheimer’s psychosis drugAcadia Pharmaceuticals presented additional data from its Phase 2 RADIANT trial of remlifanserin for Alzheimer's psychosis at a Boston conference. The 60 mg dose showed consistent efficacy signals, with 44% of patients improved versus 31.8% on placebo at Week 6, and adverse event rates similar to placebo. The company continues advancing the Phase 3 portion of the program.Business Wire BlogAcadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s DiseaseAcadia Pharmaceuticals presented additional Phase 2 RADIANT trial data on remlifanserin for Alzheimer's disease psychosis at the 2026 CTAD conference. The 60 mg once-daily dose showed a consistent efficacy signal across multiple measures, with 44% of patients improved versus 31.8% on placebo at Week 6, and safety profiles were consistent with prior findings. The company continues Phase 3 development.Stock TitanAcadia reports Phase 2 Alzheimer's psychosis trial dataAcadia Pharmaceuticals presented Phase 2 RADIANT trial data for remlifanserin in Alzheimer's disease psychosis at CTAD 2026. The 60 mg once-daily dose showed a consistent efficacy signal across multiple measures, with 44% of patients improved versus 31.8% on placebo at Week 6. The company continues Phase 3 development.TradingViewWhy ACADIA Pharmaceuticals stock is trading up todayACADIA Pharmaceuticals shares rose 2.6% after announcing an exclusive distribution agreement with KYORIN Pharmaceutical to commercialize DAYBUE STIX in Japan for Rett syndrome. The deal includes a $30 million upfront payment plus potential milestones and net sales share. Shares later fell to $19.11, up 1.9% from the previous close.Business Wire BlogAcadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in JapanAcadia Pharmaceuticals entered an exclusive distribution agreement with KYORIN Pharmaceutical to commercialize DAYBUE STIX (trofinetide) for Rett syndrome in Japan. KYORIN will handle commercialization and regulatory activities, with Acadia receiving a $30 million upfront payment and eligible for future milestone and sales share payments.